Table 4.

Heart failure outcome trials completed in 2019: comparison of results vs. placebo

DAPA-HF [22]
Class and cardiovascular/renal endpoints	HR (95% CI) p-value	Event	Event rate (%) active vs. placebo group
Primary composite endpoint		Primary composite outcome	16.3 vs. 21.2
Worsening heart failure or death from CV causes	0.74 (0.65–0.85) p < 0.01
Secondary outcome		Adverse events	No. (%) active vs. placebo group (p-value)
CV death or heart-failure hospitalization	0.75 (0.65–0.85) p < 0.001	Renal event	6.5 vs.7.2 (0.36)
Secondary outcome		Acute pancreatitis	– (–)
Total no. of hospitalizations for heart failure and CV deaths	0.75 (0.65–0.88) p < 0.001	Diabetic ketoacidosis	0.1 vs. 0a (–)
Secondary outcome
Change in KCCQ total symptom score at 8 months	1.18 (1.11–1.26) p < 0.001
Secondary outcome
Worsening renal function	0.71 (0.44–1.16)
Secondary outcome
All-cause death	0.83 (0.71–0.97)
Exploratory outcome
Cardiovascular death	0.82 (0.69–0.98)

^aAll cases of diabetic ketoacidosis occurred in patients with diabetes at baseline